ATE269708T1 - Formulierung enthaltend testosteonundecanoat und rizinusöl - Google Patents

Formulierung enthaltend testosteonundecanoat und rizinusöl

Info

Publication number: ATE269708T1
Authority: AT; Austria
Prior art keywords: solution; liquid carrier; oil; testosteonundecanoate; cascin
Prior art date: 1999-04-01

Application number

AT00920588T

Other languages

English (en)

Inventor

De Henrik Nijs

Susan Chandler

Elizabeth Anne Perry

Josephine Joan Chri Ferdinando

Original Assignee

Akzo Nobel Nv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-04-01

Filing date

2000-03-27

Publication date

2004-07-15

2000-03-27 Application filed by Akzo Nobel Nv filed Critical Akzo Nobel Nv

2004-07-15 Application granted granted Critical

2004-07-15 Publication of ATE269708T1 publication Critical patent/ATE269708T1/de

Links

238000009472 formulation Methods 0.000 title 1
239000000203 mixture Substances 0.000 title 1
239000007788 liquid Substances 0.000 abstract 3
MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 abstract 2
239000004359 castor oil Substances 0.000 abstract 2
235000019438 castor oil Nutrition 0.000 abstract 2
ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 abstract 2
229960000746 testosterone undecanoate Drugs 0.000 abstract 2
UDSFVOAUHKGBEK-CNQKSJKFSA-N testosterone undecanoate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CCCCCCCCCC)[C@@]1(C)CC2 UDSFVOAUHKGBEK-CNQKSJKFSA-N 0.000 abstract 2
239000004480 active ingredient Substances 0.000 abstract 1
239000003098 androgen Substances 0.000 abstract 1
239000002775 capsule Substances 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
239000004094 surface-active agent Substances 0.000 abstract 1
229960003604 testosterone Drugs 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Endocrinology (AREA)
Diabetes (AREA)
Reproductive Health (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Fats And Perfumes (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Steroid Compounds (AREA)
Medicines Containing Plant Substances (AREA)

AT00920588T 1999-04-01 2000-03-27 Formulierung enthaltend testosteonundecanoat und rizinusöl ATE269708T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP99302581		1999-04-01
PCT/EP2000/002677 WO2000059512A1 (en)	1999-04-01	2000-03-27	Formulation comprising testosteron undecanoate and castor oil

Publications (1)

Publication Number	Publication Date
ATE269708T1 true ATE269708T1 (de)	2004-07-15

Family

ID=8241306

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT00920588T ATE269708T1 (de)	1999-04-01	2000-03-27	Formulierung enthaltend testosteonundecanoat und rizinusöl

Country Status (26)

Country	Link
EP (1)	EP1189620B1 (de)
JP (1)	JP2002541111A (de)
KR (1)	KR100666016B1 (de)
CN (1)	CN1155385C (de)
AT (1)	ATE269708T1 (de)
AU (1)	AU768537B2 (de)
BR (1)	BR0009465A (de)
CA (1)	CA2366856C (de)
CZ (1)	CZ298573B6 (de)
DE (1)	DE60011771T2 (de)
DK (1)	DK1189620T3 (de)
ES (1)	ES2222199T3 (de)
HU (1)	HU229455B1 (de)
ID (1)	ID30481A (de)
IL (2)	IL145524A0 (de)
MX (1)	MXPA01009919A (de)
NO (1)	NO329420B1 (de)
NZ (1)	NZ514290A (de)
PL (1)	PL195163B1 (de)
PT (1)	PT1189620E (de)
RU (1)	RU2246296C2 (de)
SK (1)	SK286071B6 (de)
TR (1)	TR200102769T2 (de)
TW (1)	TWI280124B (de)
WO (1)	WO2000059512A1 (de)
ZA (1)	ZA200107781B (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9907715D0 (en) *	1999-04-01	1999-05-26	Scherer Corp R P	Pharmaceutical compositions
US6652880B1 (en)	1999-04-01	2003-11-25	R.P. Scherer Technologies, Inc.	Oral pharmaceutical compositions containing long-chain triglycerides and liphophilic surfactants
JO2505B1 (en) *	2003-03-14	2009-10-05	باير شيرنغ فارما اكتنجيسيلشافت	Pharmacy methods and formulations for obtaining acceptable serum testosterone levels
US8784869B2 (en)	2003-11-11	2014-07-22	Mattern Pharma Ag	Controlled release delivery system for nasal applications and methods of treatment
DE60303854T2 (de) *	2003-11-11	2006-08-10	Mattern, Udo	Nasenformulierung mit kontrollierter Freisetzung von Sexualhormonen
US20060140820A1 (en)	2004-12-28	2006-06-29	Udo Mattern	Use of a container of an inorganic additive containing plastic material
US8492369B2 (en)	2010-04-12	2013-07-23	Clarus Therapeutics Inc	Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same
EP1871384A4 (de)	2005-04-15	2012-01-25	Clarus Therapeutics Inc	Systeme zur pharmazeutischen verabreichung hydrophober wirkstoffe und zusammensetzungen damit
PT2068825E (pt)	2006-10-04	2011-02-11	M & P Patent Ag	Sistema de administração de libertação controlada para aplicação nasal de neurotransmissores
GB0818473D0 (en)	2008-10-08	2008-11-12	Probio Nutraceuticals As	Composition
US11304960B2 (en)	2009-01-08	2022-04-19	Chandrashekar Giliyar	Steroidal compositions
ES2525520T3 (es) *	2010-04-12	2014-12-26	Clarus Therapeutics, Inc.	Formulaciones orales de éster de testosterona y métodos para tratar la deficiencia de testosterona con las mismas
GB201006200D0 (en) *	2010-04-14	2010-06-02	Ayanda As	Composition
US9358241B2 (en)	2010-11-30	2016-06-07	Lipocine Inc.	High-strength testosterone undecanoate compositions
US9034858B2 (en)	2010-11-30	2015-05-19	Lipocine Inc.	High-strength testosterone undecanoate compositions
US20180153904A1 (en)	2010-11-30	2018-06-07	Lipocine Inc.	High-strength testosterone undecanoate compositions
US20120148675A1 (en)	2010-12-10	2012-06-14	Basawaraj Chickmath	Testosterone undecanoate compositions
PL2667877T3 (pl) *	2011-01-26	2018-09-28	Allergan, Inc.	Kompozycja androgenu do leczenia stanu okulistycznego
AR086400A1 (es)	2011-05-13	2013-12-11	Trimel Pharmaceuticals Corp	Formulaciones en gel intranasal de testosterona en dosis de menor potencia y uso de las mismas para el tratamiento de la anorgasmia o el trastorno de deseo sexual hipoactivo
US9757388B2 (en)	2011-05-13	2017-09-12	Acerus Pharmaceuticals Srl	Intranasal methods of treating women for anorgasmia with 0.6% and 0.72% testosterone gels
US20130045958A1 (en)	2011-05-13	2013-02-21	Trimel Pharmaceuticals Corporation	Intranasal 0.15% and 0.24% testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder
US11744838B2 (en)	2013-03-15	2023-09-05	Acerus Biopharma Inc.	Methods of treating hypogonadism with transnasal testosterone bio-adhesive gel formulations in male with allergic rhinitis, and methods for preventing an allergic rhinitis event
US9925200B2 (en)	2014-06-17	2018-03-27	Merck Sharp & Dohme B.V.	Stable formulations of testosterone undecanoate
AU2015276202B2 (en) *	2014-06-19	2020-09-17	Pebean Pharma Aps	Solid oral dosage form of lipophilic compounds
US9498485B2 (en)	2014-08-28	2016-11-22	Lipocine Inc.	Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters
US20170246187A1 (en)	2014-08-28	2017-08-31	Lipocine Inc.	(17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
US20160193225A1 (en) *	2014-08-29	2016-07-07	Lipocine Inc.	(17-ß)-3-OXOANDROST-4-EN-17-YL UNDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
US20160361322A1 (en)	2015-06-15	2016-12-15	Lipocine Inc.	Composition and method for oral delivery of androgen prodrugs
US11559530B2 (en)	2016-11-28	2023-01-24	Lipocine Inc.	Oral testosterone undecanoate therapy
EP3824296A4 (de) *	2018-07-20	2022-04-27	Lipocine Inc.	Lebererkrankung

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN1102095A (zh) *	1993-10-30	1995-05-03	浙江医科大学	长效雄激素类制剂——十一酸睾丸注射液
GB9415810D0 (en) *	1994-08-04	1994-09-28	Jerrow Mohammad A Z	Composition
GB9608719D0 (en) *	1996-04-26	1996-07-03	Scherer Ltd R P	Pharmaceutical compositions
SE9700642D0 (sv) *	1997-02-24	1997-02-24	Kronvall Stefan Med Ab	Medel och sätt för förebyggande och behandling av det metabola syndromet

2000
- 2000-03-27 PL PL00351259A patent/PL195163B1/pl unknown
- 2000-03-27 NZ NZ514290A patent/NZ514290A/en not_active IP Right Cessation
- 2000-03-27 HU HU0200453A patent/HU229455B1/hu unknown
- 2000-03-27 ID IDW00200102082A patent/ID30481A/id unknown
- 2000-03-27 BR BR0009465-0A patent/BR0009465A/pt not_active Application Discontinuation
- 2000-03-27 WO PCT/EP2000/002677 patent/WO2000059512A1/en not_active Ceased
- 2000-03-27 TR TR2001/02769T patent/TR200102769T2/xx unknown
- 2000-03-27 DE DE60011771T patent/DE60011771T2/de not_active Expired - Lifetime
- 2000-03-27 PT PT00920588T patent/PT1189620E/pt unknown
- 2000-03-27 AU AU41111/00A patent/AU768537B2/en not_active Expired
- 2000-03-27 RU RU2001129362/15A patent/RU2246296C2/ru active
- 2000-03-27 CA CA002366856A patent/CA2366856C/en not_active Expired - Lifetime
- 2000-03-27 AT AT00920588T patent/ATE269708T1/de active
- 2000-03-27 DK DK00920588T patent/DK1189620T3/da active
- 2000-03-27 CN CNB008059381A patent/CN1155385C/zh not_active Expired - Lifetime
- 2000-03-27 IL IL14552400A patent/IL145524A0/xx active IP Right Grant
- 2000-03-27 JP JP2000609075A patent/JP2002541111A/ja not_active Withdrawn
- 2000-03-27 KR KR1020017012498A patent/KR100666016B1/ko not_active Expired - Lifetime
- 2000-03-27 SK SK1372-2001A patent/SK286071B6/sk not_active IP Right Cessation
- 2000-03-27 EP EP00920588A patent/EP1189620B1/de not_active Expired - Lifetime
- 2000-03-27 ES ES00920588T patent/ES2222199T3/es not_active Expired - Lifetime
- 2000-03-27 CZ CZ20013507A patent/CZ298573B6/cs not_active IP Right Cessation
- 2000-03-27 MX MXPA01009919A patent/MXPA01009919A/es active IP Right Grant
- 2000-05-11 TW TW089109036A patent/TWI280124B/zh not_active IP Right Cessation
2001
- 2001-09-20 ZA ZA200107781A patent/ZA200107781B/en unknown
- 2001-09-20 IL IL145524A patent/IL145524A/en not_active IP Right Cessation
- 2001-09-28 NO NO20014718A patent/NO329420B1/no not_active IP Right Cessation

Also Published As

Publication number	Publication date
HUP0200453A2 (hu)	2002-07-29
HK1043544A1 (en)	2002-09-20
EP1189620A1 (de)	2002-03-27
ID30481A (id)	2001-12-13
EP1189620B1 (de)	2004-06-23
CA2366856C (en)	2006-05-16
CZ20013507A3 (cs)	2002-03-13
CZ298573B6 (cs)	2007-11-14
MXPA01009919A (es)	2002-04-24
CN1346274A (zh)	2002-04-24
AU768537B2 (en)	2003-12-18
BR0009465A (pt)	2002-01-08
NO329420B1 (no)	2010-10-18
SK13722001A3 (sk)	2002-02-05
NO20014718D0 (no)	2001-09-28
SK286071B6 (sk)	2008-02-05
WO2000059512A1 (en)	2000-10-12
KR100666016B1 (ko)	2007-01-10
IL145524A0 (en)	2002-06-30
DE60011771T2 (de)	2004-11-04
IL145524A (en)	2006-12-31
PT1189620E (pt)	2004-10-29
PL351259A1 (en)	2003-04-07
CN1155385C (zh)	2004-06-30
NZ514290A (en)	2003-08-29
NO20014718L (no)	2001-09-28
AU4111100A (en)	2000-10-23
HUP0200453A3 (en)	2003-06-30
DK1189620T3 (da)	2004-08-16
TWI280124B (en)	2007-05-01
HU229455B1 (en)	2013-12-30
JP2002541111A (ja)	2002-12-03
ZA200107781B (en)	2002-12-20
CA2366856A1 (en)	2000-10-12
RU2246296C2 (ru)	2005-02-20
KR20010108435A (ko)	2001-12-07
ES2222199T3 (es)	2005-02-01
DE60011771D1 (de)	2004-07-29
TR200102769T2 (tr)	2002-05-21
PL195163B1 (pl)	2007-08-31

Legal Events

Date

Code

Title

Description

2005-02-15

UEP

Publication of translation of european patent specification

Ref document number: 1189620

Country of ref document: EP

Publication	Publication Date	Title
ATE269708T1 (de)	2004-07-15	Formulierung enthaltend testosteonundecanoat und rizinusöl
RU2001129362A (ru)	2003-08-27	Композиция, включающая ундеканоат тестостерона и касторовое масло
DK1173153T3 (da)	2006-02-20	Orale farmaceutiske præparater, som indeholder langkædede triglycerider og lipofile overfladeaktive midler
CA2185347A1 (en)	1995-09-21	A carrier for hydrophobic drugs and a pharmaceutical composition based thereon
PL318560A1 (en)	1997-06-23	Novel orally administered preparations containing cyclosporin of simple composition and high bioavailability
KR950031069A (ko)	1995-12-18	골손실의 억제 및 혈청 콜레스테롤의 강하 방법
NZ543250A (en)	2008-12-24	Pharmaceutical compositions for hepatitis C viral protease inhibitors
IL165601A0 (en)	2006-01-15	Oral pharmaceutical forms of liquid drugs having improved bioavailability
WO2000057918A2 (en)	2000-10-05	Novel formulations comprising lipid-regulating agents
ES2110377T1 (es)	1998-02-16	Formulacion galenica de fenofibrato y aplicacion de la misma.
WO2004012680B1 (en)	2004-08-05	Lipid-drug complexes in reversed liquid and liquid crystalline phases
BRPI0008228B1 (pt)	2016-08-23	composição farmacêutica contendo n-benzoil estaurosporina e agentes solubilizantes
IT1263840B (it)	1996-09-04	Formulazioni orali di ubidecarenone in forma di capsule
NO950134L (no)	1995-09-04	Formuleringer for oralt administrerte farmasöytiske midler
US20010006658A1 (en)	2001-07-05	Novel formulations comprising lipid-regulating agents
KR970705997A (ko)	1997-11-03	N-{4-[2-(1, 2, 3, 4-테트라히드로-6, 7-디메톡시-2-이소퀴놀리닐)-에틸]-페닐}-9, 10-디히드로-5-메톡시-9-옥소-4-아크리딘 카르복사미드 화합물(gf120918a)을 포함하는 비경구 제약 조성물(parenteral pharmaceutical compositions containing gf120918a)
MXPA04000535A (es)	2004-05-04	FORMULACIONES ANTIHISTAMINICAS PARA FORMAS DE DOSIFICACION DE CaPSULAS SUAVES.
AR023235A1 (es)	2002-09-04	Formulaciones de androgenos
MXPA05008921A (es)	2005-10-05	Formulaciones orales semisolidas para liberacion inmediata que comprenden un agente hidrofobo anticancer, un glicerido poliglicolisado y un vehiculo hidrofilo.
KR20050030281A (ko)	2005-03-30	가용성 로바스타틴의 연질캡슐제 조성물 및 그의 제조방법
AU3043400A (en)	2000-07-31	Cyclosporin solution
US20060024341A1 (en)	2006-02-02	Microemulsion composition and related method
TH33003B (th)	2012-06-29	สูตรตำรับแอนโดรเจน
TH60756A (th)	2004-02-13	สูตรตำรับแอนโดรเจน
TH34374B (th)	2012-11-21	องค์ประกอบเชิงเภสัชกรรมชนิดที่เป็นของแข็งซึ่งประกอบด้วยอนุพันธ์เบนโซฟูแรน